ENDRA Life Sciences Inc. — Form 8-K Summary
Report date: October 1, 2026. This filing reports amendments related to ENDRA’s proposed merger with ASP Isotopes Inc. subsidiaries Noble Africa LLC and Renergen Limited. The merger agreement, originally dated June 25, 2026, provides for ENDRA’s subsidiary to merge into Noble, with Noble surviving as an ENDRA subsidiary, subject to closing conditions.
Key transaction changes
- The parties amended the merger agreement to remove the requirement for the post-merger board to be divided into three classes and updated the proposed certificate of incorporation to remove classified-board and certain supermajority-vote provisions.
- The minimum-cash closing condition was revised to $3,800,002.59, less certain agreed expenses related to investor-relations activities. The filing does not provide a resulting net minimum-cash figure.
- The amendment permits Renergen to enter a fifth addendum increasing its borrowing capacity under an ASPI term-loan facility from $80 million to up to $120 million. It also contemplates a sixth addendum at or before merger closing that could increase capacity from $120 million to up to $200 million. These are borrowing-capacity limits, not stated amounts borrowed.
- ENDRA amended warrants issued to an ASPI affiliate to remove the 4.99% beneficial-ownership exercise limitation. Other warrant terms remain in effect except as amended.
Warrant and potential dilution details
The May 2026 private placement included 66,846 common shares, pre-funded warrants for up to 511,541 shares at a $0.0001 exercise price, and common warrants for up to 1,156,774 shares at a $6.57 exercise price. The filing states that pre-funded warrants covering 324,372 shares and all common warrants require ENDRA stockholder approval before becoming exercisable.
Financial condition and operating results
This 8-K does not report revenue, profit, cash flow, margins, debt balances, or periodic operating results. It gives a revised merger-closing cash threshold but no current cash or liquidity balance for ENDRA or the combined company. The filing also does not quantify any expected financing proceeds or amounts drawn under Renergen’s facility.
Outlook, risks, and contingencies
The merger and related financing remain proposed and subject to conditions, including stockholder and other required approvals. The filing identifies risks including failure or delay in completing the merger or financings, obtaining debt on acceptable terms, Nasdaq listing status, cash use and transaction costs, potential termination of the merger agreement, and Renergen’s funding needs and project execution. It specifically notes uncertainty around potential U.S. DFC or Standard Bank SA funding and development of the Virginia Gas Project. No assurance is given that the proposed transactions will close or that anticipated benefits will be realized.
Important facts for investors to verify
- Whether ENDRA stockholders approve the merger and warrant-share issuances, and whether all other closing conditions are satisfied.
- The actual closing cash position and the expenses deducted from the revised minimum-cash threshold.
- Whether the fifth and contemplated sixth loan addenda are executed, and the amounts and terms of any borrowing.
- The eventual Form S-4 and proxy statement, including transaction terms, dilution, financing details, and participant interests.
- ENDRA’s and ASPI’s latest SEC filings for current liquidity, listing status, and risk disclosures.